What's breaking now, across thousands of outlets.
Kura Oncology, the maker of the leukemia menin inhibitor Komzifti, is spinning out its diabetes R&D to a new company that has attracted the attention of the leading pharma in the metabolic ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
The business of advancing shelved pharma assets continues to reap benefits, this time for Beeline Medicines and a lupus candidate provided by Bristol Myers Squibb.
Tyra Biosciences wants to challenge Johnson & Johnson in a low-risk form of bladder cancer. The Phase 2 data it released Wednesday takes a step toward that goal — although you just might have to…
A new blood-based screening algorithm dramatically reduced the number of unnecessary PET scans needed to recruit patients at risk of Alzheimer's disease for a clinical trial, according to research…
Pfizer and Merck KGaA's venture groups are backing a nimble cancer startup taking a different approach to the popular antibody-drug conjugate and radioligand fields.
After tinkering with the biology of the broadly appealing anti-inflammatory NLRP3 pathway, NodThera is now plotting its pivotal trial plans for 2027.
Bangladesh has been racing to halt the measles outbreak spread since March, when more than 100 children died in less than a month.
